Associations Between Molecular Classifications of Colorectal Cancer and Patient Survival: A Systematic Review

[1]  D. Sargent,et al.  Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer , 2017, Journal of the National Cancer Institute.

[2]  P. Laurent-Puig,et al.  Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  D. Sargent,et al.  Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  S. Baylin,et al.  Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients , 2016, Oncotarget.

[5]  M. Kloor,et al.  No association of CpG island methylator phenotype and colorectal cancer survival: population-based study , 2016, British Journal of Cancer.

[6]  E. Furth,et al.  Clinicopathogenomic analysis of mismatch repair proficient colorectal adenocarcinoma uncovers novel prognostic subgroups with differing patterns of genetic evolution , 2016, International journal of cancer.

[7]  R. Pai,et al.  MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas , 2016, The American journal of surgical pathology.

[8]  Nan Song,et al.  Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial. , 2016, JAMA oncology.

[9]  Susan Halabi,et al.  American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine , 2016, CA: a cancer journal for clinicians.

[10]  S. Ogino,et al.  Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  F. Sinicrope,et al.  Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  P. Laurent-Puig,et al.  Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. , 2016, JAMA oncology.

[13]  G. Kang,et al.  Molecular Subtypes of Colorectal Cancer and Their Clinicopathologic Features, With an Emphasis on the Serrated Neoplasia Pathway. , 2016, Archives of pathology & laboratory medicine.

[14]  J. Galon,et al.  Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. , 2016, International immunology.

[15]  Z. Trajanoski,et al.  Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. , 2016, Immunity.

[16]  H. Brenner,et al.  Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review , 2016, Clinical Epigenetics.

[17]  M. Kloor,et al.  The Immune Biology of Microsatellite-Unstable Cancer. , 2016, Trends in cancer.

[18]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[19]  S. Kato,et al.  Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer , 2015, International Journal of Clinical Oncology.

[20]  T. Kuopio,et al.  Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer , 2015, British Journal of Cancer.

[21]  M. Scarpelli,et al.  Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab , 2015, Journal of Translational Medicine.

[22]  K. Søreide,et al.  Molecular Subtypes in Stage II-III Colon Cancer Defined by Genomic Instability: Early Recurrence-Risk Associated with a High Copy-Number Variation and Loss of RUNX3 and CDKN2A , 2015, PloS one.

[23]  E. Masiero,et al.  Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer. , 2015, Future oncology.

[24]  G. Collins,et al.  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement , 2015, Annals of Internal Medicine.

[25]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation , 2015, BMJ : British Medical Journal.

[26]  S. Baylin,et al.  Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  M. Bertagnolli,et al.  CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. , 2014, Gastroenterology.

[28]  Hermann Brenner,et al.  Colorectal cancer , 2014, The Lancet.

[29]  Xin Wang,et al.  Reconciliation of classification systems defining molecular subtypes of colorectal cancer , 2014, Cell cycle.

[30]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[31]  Andreas Schlicker,et al.  Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition , 2013, International journal of cancer.

[32]  N. Cho,et al.  Loss of CDX2/CK20 Expression Is Associated With Poorly Differentiated Carcinoma, the CpG Island Methylator Phenotype, and Adverse Prognosis in Microsatellite-unstable Colorectal Cancer , 2013, The American journal of surgical pathology.

[33]  Reiko Nishihara,et al.  Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. , 2013, Journal of the National Cancer Institute.

[34]  J. Cerhan,et al.  Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. , 2013, Gastroenterology.

[35]  R. Palmqvist,et al.  The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer , 2013, British Journal of Cancer.

[36]  Mira Ayadi,et al.  Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value , 2013, PLoS medicine.

[37]  Lewis C Cantley,et al.  A colorectal cancer classification system that associates cellular phenotype and responses to therapy , 2013, Nature Medicine.

[38]  Florian Markowetz,et al.  Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions , 2013, Nature Medicine.

[39]  Aung Ko Win,et al.  KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers , 2013, British Journal of Cancer.

[40]  D. Kerr,et al.  Use of multivariate analysis to suggest a new molecular classification of colorectal cancer , 2013, The Journal of pathology.

[41]  Reiko Nishihara,et al.  Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers , 2012, Clinical Cancer Research.

[42]  Javier Sastre,et al.  Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior , 2012, BMC Cancer.

[43]  D. Sargent,et al.  Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications , 2012, Clinical Cancer Research.

[44]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[45]  E. Dogliotti,et al.  Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. , 2010, European journal of cancer.

[46]  B. Leggett,et al.  Role of the serrated pathway in colorectal cancer pathogenesis. , 2010, Gastroenterology.

[47]  Ajay Goel,et al.  Microsatellite instability in colorectal cancer. , 2010, Gastroenterology.

[48]  Sabine Tejpar,et al.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  M. Bertagnolli,et al.  Molecular origins of cancer: Molecular basis of colorectal cancer. , 2009, The New England journal of medicine.

[50]  G. Casey,et al.  Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer , 2009, The British journal of surgery.

[51]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[52]  Shuji Ogino,et al.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.

[53]  J. Jass.  Classification of colorectal cancer based on correlation of clinical, morphological and molecular features , 2007, Histopathology.

[54]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[55]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[57]  M. Mendiola,et al.  Clinical relevance of colorectal cancer molecular subtypes. , 2017, Critical reviews in oncology/hematology.

[58]  D. Sargent,et al.  Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. , 2015, Gastroenterology.

[59]  P. Laird,et al.  Association between molecular subtypes of colorectal cancer and patient survival. , 2015, Gastroenterology.

[60]  Francesco Bertoni,et al.  Hierarchical clustering analysis of pathologic and molecular data identifies prognostically and biologically distinct groups of colorectal carcinomas , 2011, Modern Pathology.

[61]  S. Ogino,et al.  Molecular classification and correlates in colorectal cancer. , 2008, The Journal of molecular diagnostics : JMD.